Atara Biotherapeutics (ATRA) Operating Income (2013 - 2026)

Atara Biotherapeutics has reported Operating Income for 14 years, with the latest figure at -$3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income fell 108.68% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at -$35.3 million (down 163.65% YoY), and the FY2025 full-year result was $6.9 million, up 108.23% from the prior year.
• Operating Income for Q1 2026 stood at -$3.4 million, up from -$31.6 million in the prior quarter.
• The five-year high for Operating Income was $38.8 million in Q1 2025, with the low at -$88.2 million in Q1 2022.
• Historically, Operating Income has averaged -$37.4 million across 5 years, with a median of -$31.6 million in 2025.
• The largest YoY upside for Operating Income was 224.18% in 2025 against a maximum downside of 158.58% in 2025.
• Atara Biotherapeutics' Operating Income stood at -$75.5 million in 2022, then climbed by 20.62% to -$60.0 million in 2023, then soared by 79.65% to -$12.2 million in 2024, then plunged by 158.58% to -$31.6 million in 2025, then soared by 89.32% to -$3.4 million in 2026.
• The last three Operating Income figures came in at -$3.4 million (Q1 2026), -$31.6 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.